These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1449383)

  • 1. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia.
    Buchsbaum MS; Potkin SG; Siegel BV; Lohr J; Katz M; Gottschalk LA; Gulasekaram B; Marshall JF; Lottenberg S; Teng CY
    Arch Gen Psychiatry; 1992 Dec; 49(12):966-74. PubMed ID: 1449383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol.
    Holcomb HH; Cascella NG; Thaker GK; Medoff DR; Dannals RF; Tamminga CA
    Am J Psychiatry; 1996 Jan; 153(1):41-9. PubMed ID: 8540590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients.
    Siegel BV; Buchsbaum MS; Bunney WE; Gottschalk LA; Haier RJ; Lohr JB; Lottenberg S; Najafi A; Nuechterlein KH; Potkin SG
    Am J Psychiatry; 1993 Sep; 150(9):1325-36. PubMed ID: 8352343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task.
    Shihabuddin L; Buchsbaum MS; Hazlett EA; Haznedar MM; Harvey PD; Newman A; Schnur DB; Spiegel-Cohen J; Wei T; Machac J; Knesaurek K; Vallabhajosula S; Biren MA; Ciaravolo TM; Luu-Hsia C
    Arch Gen Psychiatry; 1998 Mar; 55(3):235-43. PubMed ID: 9510217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal size and relative glucose metabolic rate in schizotypal personality disorder and schizophrenia.
    Shihabuddin L; Buchsbaum MS; Hazlett EA; Silverman J; New A; Brickman AM; Mitropoulou V; Nunn M; Fleischman MB; Tang C; Siever LJ
    Arch Gen Psychiatry; 2001 Sep; 58(9):877-84. PubMed ID: 11545672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms.
    Wolkin A; Sanfilipo M; Duncan E; Angrist B; Wolf AP; Cooper TB; Brodie JD; Laska E; Rotrosen JP
    Am J Psychiatry; 1996 Mar; 153(3):346-54. PubMed ID: 8610821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography.
    Wolkin A; Jaeger J; Brodie JD; Wolf AP; Fowler J; Rotrosen J; Gomez-Mont F; Cancro R
    Am J Psychiatry; 1985 May; 142(5):564-71. PubMed ID: 3872603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients.
    Bartlett EJ; Brodie JD; Simkowitz P; Schlösser R; Dewey SL; Lindenmayer JP; Rusinek H; Wolkin A; Cancro R; Schiffer W
    Am J Psychiatry; 1998 Mar; 155(3):337-43. PubMed ID: 9501742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder.
    Pearlson GD; Wong DF; Tune LE; Ross CA; Chase GA; Links JM; Dannals RF; Wilson AA; Ravert HT; Wagner HN
    Arch Gen Psychiatry; 1995 Jun; 52(6):471-7. PubMed ID: 7771917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-deoxyglucose in affective illness.
    Buchsbaum MS; Wu J; DeLisi LE; Holcomb H; Kessler R; Johnson J; King AC; Hazlett E; Langston K; Post RM
    J Affect Disord; 1986; 10(2):137-52. PubMed ID: 2941470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: differences between normal controls and schizophrenic patients.
    Buchsbaum MS; Wu JC; DeLisi LE; Holcomb HH; Hazlett E; Cooper-Langston K; Kessler R
    Biol Psychiatry; 1987 Apr; 22(4):479-94. PubMed ID: 2882788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects.
    Bartlett EJ; Brodie JD; Simkowitz P; Dewey SL; Rusinek H; Wolf AP; Fowler JS; Volkow ND; Smith G; Wolkin A
    Am J Psychiatry; 1994 May; 151(5):681-6. PubMed ID: 8166309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.
    Wong DF; Wagner HN; Tune LE; Dannals RF; Pearlson GD; Links JM; Tamminga CA; Broussolle EP; Ravert HT; Wilson AA; Toung JK; Malat J; Williams JA; O'Tuama LA; Snyder SH; Kuhar MJ; Gjedde A
    Science; 1986 Dec; 234(4783):1558-63. PubMed ID: 2878495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clozapine effects on glucose metabolic rate in striatum and frontal cortex.
    Potkin SG; Buchsbaum MS; Jin Y; Tang C; Telford J; Friedman G; Lottenberg S; Najafi A; Gulasekaram B; Costa J
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():63-6. PubMed ID: 7961576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia.
    Szechtman H; Nahmias C; Garnett ES; Firnau G; Brown GM; Kaplan RD; Cleghorn JM
    Arch Gen Psychiatry; 1988 Jun; 45(6):523-32. PubMed ID: 2897836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
    Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
    Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
    Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study.
    Klein E; Bental E; Lerer B; Belmaker RH
    Arch Gen Psychiatry; 1984 Feb; 41(2):165-70. PubMed ID: 6365015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.